Global Partners LP·Energy

Citi said Eli Lilly and Co's (NYSE:LLY) experimental obesity drug retatrutide has set a new competitive benchmark for the GLP-1 weight-loss market after a pivotal trial showed patients losing 28% of their body weight over 80 weeks at the highest dose. The results from the TRIUMPH-1 trial, the first dedicated phase III obesity study of the triple agonist drug, were broadly in line with the previously reported TRIUMPH-4 trial in obesity and knee osteoarthritis patients, which showed 28.7% weight loss at 68 weeks.

With a mean weight loss of 16.6%1, Wegovy® pill demonstrates best-in-class weight-loss efficacy and is the first oral GLP-1 treatment recommended by CHMP for weight management in the EU. CHMP recommends Wegovy® pill for approval to reduce excess body weight and maintain long-term weight reduction.

Eli Lilly's investigational drug, retatrutide, delivered an average 80-week weight loss of 70 pounds at the highest dose.

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform in Canada. This is Hims & Hers' first international generic GLP-1 offering, demonstrating the company's ability to meet the unique needs of each global market it serves while continuing its international expansion efforts. Personalized treatment plans are available starting at $149 CAD/month, making.

Shares of Eli Lilly and Company NYSE: LLY, the world's most valuable pharmaceutical stock, started 2026 in a bad way. Near the end of April, LLY shares had fallen as much as 20%.

Deutsche Bank has maintained its 'hold' rating on Novo Nordisk (NYSE:NVO) with a price target of DKK290 after hosting the Danish drugmaker's head of research and development, Martin Lange. Analyst Emmanuel Papadakis said the key takeaway was that Novo is cautiously optimistic its cagrisema RD11 obesity study will yield a better result than the earlier RD4 trial, which disappointed markets when data was released.
Global Partners LP engages in the purchasing, selling, gathering, blending, storing, and logistics of transporting gasoline and gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, and propane to wholesalers, retailers, and commercial customers in the New England states, Mid-Atlantic region, and New York. The company is also involved in the transportation of petroleum products and renewable fuels through rail from the mid-continent region of the United States and Canada. Its Wholesale segment sells home heating oil, branded and unbranded gasoline and gasoline blendstocks, diesel, kerosene, residual oil, and propane to home heating oil retailers and wholesale distributors. It also aggregates crude oil through truck or pipeline in the mid-continent region of the United States and Canada, as well as transports it through rail and ships it through barge to refiners. The company's Gasoline Distribution and Station Operations segment sells branded and unbranded gasoline to gasoline station operators and sub-jobbers; operates gasoline stations and convenience stores; and provides car wash, lottery, and ATM services, as well as leases gasoline stations. Its Commercial segment sells and delivers unbranded gasoline, home heating oil, diesel, kerosene, residual oil, and bunker fuel to customers in the public sector, as well as to commercial and industrial end-users; and sells custom blended fuels. As of December 31, 2021, the company had a portfolio of 1,595 owned, leased, and supplied gasoline stations, which included 295 directly operated convenience stores; and owned, leased, or maintained storage facilities at 26 bulk terminals with a collective storage capacity of 11.9 million barrels. Global GP LLC serves as the general partner of the company. The company was incorporated in 2005 and is based in Waltham, Massachusetts.
Energy
Oil & Gas Midstream
3,300
2005-09-29
1.04